Background: Morbidity and mortality from congenital and acquired cardiovascular (CV) disease is increased in Turner syndrome (TS), where traditional indices of CV risk are widely present but the single most common feature remains estrogen deficiency. Aim: To investigate CV risk in TS as expressed by the widely available ambulatory arterial stiffness index (AASI) and the impact of female sex hormone replacement therapy (HRT) hereon. Methods: TS women (n = 26) were examined following HRT washout and again during 6 months of HRT. Age-matched healthy female controls (n = 24) were examined once. 24-Hour ambulatory blood pressures, AASI in addition to metabolic and anthropometric indices of CV risk were measured. Results: The relatively tachycardic TS women had higher systolic and diastolic blood pressures. HRT reduced diastolic blood pressures with an increase in physical fitness, worsening of glucose tolerance, and a reduction in high-density lipoprotein. AASI was significantly elevated in TS when compared to controls (0.36 (0.02) vs. 0.26 (0.03), p = 0.01) but unaffected by HRT. Major explanatory variables to AASI were status (being TS or not), age, and diurnal pulse variability. Conclusion: AASI was elevated in TS, possibly indicating elevated CV risk with no impact of short-term HRT.

Keywords:
Cardiovascular risk, Turner syndrome, Estrogen replacement therapy, Insulin resistance, Hypertension
1.
Stochholm K, Juul S, Juel K, Naeraa RW, Gravholt CH: Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. J Clin Endocrinol Metab 2006;91:3897–3902.
2.
Gravholt CH, Naeraa RW, Nyholm B, Gerdes LU, Christiansen E, Schmitz O, Christiansen JS: Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner’s syndrome. The impact of sex hormone replacement. Diabetes Care 1998;21:1062–1070.
3.
Elsheikh M, Casadei B, Conway GS, Wass JA: Hypertension is a major risk factor for aortic root dilatation in women with Turner’s syndrome. Clin Endocrinol (Oxf) 2001;54:69–73.
4.
Nathwani NC, Unwin R, Brook CG, Hindmarsh PC: Blood pressure and Turner syndrome. Clin Endocrinol (Oxf) 2000;52:363–370.
5.
Gravholt CH, Juul S, Naeraa RW, Hansen J: Morbidity in Turner syndrome. J Clin Epidemiol 1998;51:147–158.
6.
Gravholt CH, Hansen KW, Erlandsen M, Ebbehoj E, Christiansen JS: Nocturnal hypertension and impaired sympathovagal tone in Turner syndrome. J Hypertens 2006;24:353–360.
7.
Andersen NH, Hjerrild BE, Sorensen K, Pedersen EM, Stochholm K, Gormsen LC, Horlyck A, Christiansen JS, Gravholt CH: Subclinical left ventricular dysfunction in normotensive women with Turner’s syndrome. Heart 2006;92:1516–1517.
8.
Ostberg JE, Donald AE, Halcox JP, Storry C, McCarthy C, Conway GS: Vasculopathy in Turner syndrome: arterial dilatation and intimal thickening without endothelial dysfunction. J Clin Endocrinol Metab 2005;90:5161–5166.
9.
Sybert VP: Cardiovascular malformations and complications in Turner syndrome. Pediatrics 1998;101:E11.
10.
Landin-Wilhelmsen K, Bryman I, Wilhelmsen L: Cardiac malformations and hypertension, but not metabolic risk factors, are common in Turner syndrome. J Clin Endocrinol Metab 2001;86:4166–4170.
11.
Gotzsche CO, Krag-Olsen B, Nielsen J, Sorensen KE, Kristensen BO: Prevalence of cardiovascular malformations and association with karyotypes in Turner’s syndrome. Arch Dis Child 1994;71:433–436.
12.
Dawson-Falk KL, Wright AM, Bakker B, Pitlick PT, Wilson DM, Rosenfeld RG: Cardiovascular evaluation in Turner syndrome: utility of MR imaging. Australas Radiol 1992;36:204–209.
13.
Gravholt CH: Turner syndrome and the heart: cardiovascular complications and treatment strategies. Am J Cardiovasc Drugs 2002;2:401–413.
14.
Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM: Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: Insights from basic science and clinical studies. Endocr Rev 2006;27:575–605.
15.
Teede HJ: Sex hormones and the cardiovascular system: effects on arterial function in women. Clin Exp Pharmacol Physiol 2007;34:672–676.
16.
Li Y, Wang JG, Dolan E, Gao PJ, Guo HF, Nawrot T, Stanton AV, Zhu DL, O’Brien E, Staessen JA: Ambulatory arterial stiffness index derived from 24-hour ambulatory blood pressure monitoring. Hypertension 2006;47:359–364.
17.
Hansen TW, Li Y, Staessen JA, Jeppesen J, Rasmussen S, Wang JG, Thijs L, Ibsen H, Safar ME, Torp-Pedersen C: Independent prognostic value of the ambulatory arterial stiffness index and aortic pulse wave velocity in a general population. J Hum Hypertens 2008;22:214–216.
18.
Leoncini G, Ratto E, Viazzi F, Vaccaro V, Parodi A, Falqui V, Conti N, Tomolillo C, Deferrari G, Pontremoli R: Metabolic syndrome and ambulatory arterial stiffness index in non-diabetic patients with primary hypertension. J Hum Hypertens 2007;21:802–807.
19.
Leoncini G, Ratto E, Viazzi F, Vaccaro V, Parodi A, Falqui V, Conti N, Tomolillo C, Deferrari G, Pontremoli R: Increased ambulatory arterial stiffness index is associated with target organ damage in primary hypertension. Hypertension 2006;48:397–403.
20.
Kikuya M, Staessen JA, Ohkubo T, Thijs L, Metoki H, Asayama K, Obara T, Inoue R, Li Y, Dolan E, Hoshi H, Hashimoto J, Totsune K, Satoh H, Wang JG, O’Brien E, Imai Y: Ambulatory arterial stiffness index and 24-hour ambulatory pulse pressure as predictors of mortality in Ohasama, Japan. Stroke 2007;38:1161–1166.
21.
Gravholt CH, Weis NR: Reference values for body proportions and body composition in adult women with Ullrich-Turner syndrome. Am J Med Genet 1997;72:403–408.
22.
Heitmann BL: Prediction of body water and fat in adult Danes from measurement of electrical impedance. A validation study. Int J Obes 1990;14:789–802.
23.
Pacini G, Bergman RN: MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed 1986;23:113–122.
24.
Bergman RN, Ider YZ, Bowden CR, Cobelli C: Quantitative estimation of insulin sensitivity. Am J Physiol 1979;236:E667–E677.
25.
Elsheikh M, Bird R, Casadei B, Conway GS, Wass JA: The effect of hormone replacement therapy on cardiovascular hemodynamics in women with Turner’s syndrome. J Clin Endocrinol Metab 2000;85:614–618.
26.
Chan NN, Vallance P, Colhoun HM, MacAllister RJ, Hingorani AD, Conway GS: The effects of hormone replacement therapy on endothelial function in women with Turner’s syndrome. Clin Endocrinol (Oxf) 2002;56:615–620.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.